Resultados globales: 4 registros encontrados en 0.02 segundos.
Artículos, Encontrados 4 registros
Artículos Encontrados 4 registros  
1.
10 p, 685.7 KB Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia : the phase 2 CAPTIVATE study / Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Solman, Isabelle G. (Pharmacyclics LLC. an AbbVie Company) ; Tam, Constantine S. (Monash University) ; Grigg, Andrew (Austin Hospital) ; Scarfò, Lydia (Università Vita Salute San Raffaele) ; Kipps, Thomas J. (University of California. Moores Cancer Center) ; Srinivasan, Srimathi (Janssen Research & Development) ; Mali, Raghuveer Singh (Pharmacyclics LLC. an AbbVie Company) ; Zhou, Cathy (Pharmacyclics LLC. an AbbVie Company) ; Dean, James P. (Pharmacyclics LLC. an AbbVie Company) ; Szafer Glusman, Edith (Pharmacyclics LLC. an AbbVie Company) ; Choi, Michael (University of California)
We evaluated immune cell subsets in patients with chronic lymphocytic leukemia (CLL) who received first-line therapy with 3 cycles of ibrutinib then 13 cycles of ibrutinib plus venetoclax in the minimal residual disease (MRD) cohort of the CAPTIVATE study (NCT02910583). [...]
2023 - 10.1182/bloodadvances.2023010236
Blood advances, Vol. 7 Núm. 18 (26 2023) , p. 5294-5309  
2.
9 p, 996.2 KB Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia : Extended phase 3 results from RESONATE-2 / Barr, Paul M. (University of Rochester) ; Robak, Tadeusz (Medical University of Lodz) ; Owen, Carolyn (Tom Baker Cancer Centre) ; Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ; Bairey, Osnat (Sackler Faculty of Medicine. Tel Aviv University) ; Bartlett, Nancy L. (Washington University School of Medicine) ; Burger, Jan A. (University of Texas MD Anderson Cancer Center) ; Hillmen, Peter (The Leeds Teaching Hospitals. St. James Institute of Oncology) ; Coutre, Steven E (Stanford University School of Medicine) ; Devereux, Stephen (Kings College Hospital) ; Grosicki, Sebastian (School of Public Health. Silesian Medical University) ; McCarthy, Helen (Royal Bournemouth Hospital) ; Li, Jianyong (Jiangsu Province Hospital) ; Simpson, David (North Shore Hospital) ; Offner, Fritz (Universitair Ziekenhuis Gent) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Zhou, Cathy (Pharmacyclics. LLC an AbbVie Company) ; Styles, Lori (Pharmacyclics. LLC an AbbVie Company) ; James, Danelle (Pharmacyclics. LLC an AbbVie Company) ; Kipps, Thomas J (University of California,San Diego. Moores Cancer Center) ; Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele) ; Universitat Autònoma de Barcelona
Results of RESONATE-2 (PCYC-1115/1116) supported approval of ibrutinib for first-line treatment of chronic lymphocytic Rleukemia. Extended analysis of RESONATE-2 was conducted to determine long-term efficacy and safety of ibrutinib in older patients with chronic lymphocytic leukemia. [...]
2018 - 10.3324/haematol.2018.192328
Haematologica, Vol. 103 Núm. 9 (31 2018) , p. 1502-1510  
3.
15 p, 664.9 KB Ibrutinib plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia : Primary Analysis Results from the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study / Wierda, W. G. (University of Texas.) ; Allan, J. N. (Weill Cornell Medicine) ; Siddiqi, T. (City of Hope National Medical Center) ; Kipps, T. J. (UCSD. Moores Cancer Center) ; Opat, S. (Monash University) ; Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ; Badoux, X. C. (Ministry of Health) ; Kuss, B. J. (Flinders University. Medical Centre) ; Jackson, S. (Middlemore Hospital) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Jacobs, R. M. D. (Levine Cancer Institute) ; Pagel, J. M. (Swedish Cancer Institute. Center for Blood Disorders and Stem Cell Transplantation) ; Flinn, I. (Sarah Cannon Research Institute. Tennessee Oncology) ; Pak, Y. (Pharmacyclics LLC. AbbVie Company) ; Zhou, Cathy (Pharmacyclics LLC. AbbVie Company) ; Szafer-Glusman, E. (Pharmacyclics LLC. AbbVie Company) ; Ninomoto, J. (Pharmacyclics LLC. AbbVie Company) ; Dean, James P (Pharmacyclics LLC. AbbVie Company) ; James, D. F. (Pharmacyclics LLC. AbbVie Company) ; Ghia, Paolo (Università Vita-Salute San Raffaele. IRCCS Ospedale San Raffaele) ; Tam, C. S. (Peter MacCallum Cancer Center. St Vincent's Hospital. University of Melbourne) ; Universitat Autònoma de Barcelona
PURPOSE CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leukemia (CLL). [...]
2021 - 10.1200/JCO.21.00807
Journal of Clinical Oncology, Vol. 39 Núm. 34 (january 2021) , p. 3853-3865  
4.
10 p, 631.8 KB Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL : analysis from the iLLUMINATE study / Greil, Richard (Salzburg Cancer Research Institute-CCCIT, Cancer Cluster Salzburg. IIIrd Medical Department Paracelsus Medical University) ; Tedeschi, Alessandra (Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Anz, Bertrand (Tennessee Oncology. Department of Medical Oncology) ; Larratt, Loree (University of Alberta Hospital. Department of Clinical Hematology) ; Simkovic, Martin (University Hospital Hradec Kralove (República Txeca)) ; Gill, Devinder (Princess Alexandra Hospital. Department of Clinical Hematology) ; Gribben, John G. (Queen Mary University of London, Barts Cancer Institute. Centre for Haemato-Oncology) ; Flinn, Ian W. (Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology. Center for Blood Cancers) ; Wang, Zhengyuan (Pharmacyclics LLC, an AbbVie Company. Translational Medicine) ; Cheung, Leo W. K. (Pharmacyclics LLC, an AbbVie Company. Translational Medicine) ; Nguyen, Aaron N. (Pharmacyclics LLC, an AbbVie Company. Translational Medicine) ; Zhou, Cathy (Pharmacyclics LLC, an AbbVie Company. Biostatistics) ; Styles, Lori (Pharmacyclics LLC, an AbbVie Company. Clinical Science) ; Demirkan, Fatih (Dokuz Eylül University. Department of Hematology) ; Universitat Autònoma de Barcelona
The online version contains supplementary material available at 10. 1007/s00277-021-04536-6.
2021 - 10.1007/s00277-021-04536-6
Annals of Hematology, Vol. 100 (may 2021) , p. 1733-1742  

Vea también: autores con nombres similares
176 Zhou, C.
1 Zhou, Caicun
1 Zhou, Caicun
1 Zhou, Ccathy
1 Zhou, Chao
3 Zhou, Chen
1 Zhou, Chensheng W.
1 Zhou, Chongran
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.